Radiopharm Theranostics Reports Decline in Cash at End of March
-- Radiopharm Theranostics (ASX:RAD) said it closed the March quarter with a cash position of AU$19.2 million, down from AU$34.5 million at the end of the previous quarter, according to a Thursday filing with the Australian bourse.
The company reported net cash outflows from operating activities of AU$14.9 million for the quarter, with direct research and development expenses and staff costs representing 95% of the total.
Radiopharm Theranostics has completed enrolment in a phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases, and has also received a positive recommendation from the Data and Safety Monitoring Committee to advance its RAD 202 radiopharmaceutical therapy candidate to the next dose level, per the filing.